354 related articles for article (PubMed ID: 27770790)
1. Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients.
Wolf B; Goebel G; Hackl H; Fiegl H
BMC Cancer; 2016 Oct; 16(1):821. PubMed ID: 27770790
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance of β -tubulin isotype III gene expression in breast cancer patients.
He Q; Peng B; Zhuang D; Xiao L; Zheng L; Fan Z; Zhu J; Xu B; Xu C; Zhao J; Wu L; Zhou P; Hou L; Yu F; Zhao G
Cancer Biomark; 2015; 15(6):823-31. PubMed ID: 26406408
[TBL] [Abstract][Full Text] [Related]
3. Interactions between FGFR2 and RSK2-implications for breast cancer prognosis.
Czaplinska D; Mieczkowski K; Supernat A; Skladanowski AC; Kordek R; Biernat W; Zaczek AJ; Romanska HM; Sadej R
Tumour Biol; 2016 Oct; 37(10):13721-13731. PubMed ID: 27476168
[TBL] [Abstract][Full Text] [Related]
4. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
[TBL] [Abstract][Full Text] [Related]
5. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S
J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688
[TBL] [Abstract][Full Text] [Related]
6. MiR-4728-3p could act as a marker of HER2 status.
Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
[TBL] [Abstract][Full Text] [Related]
7. Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients.
Tjensvoll K; Oltedal S; Farmen RK; Shammas FV; Heikkilä R; Kvaløy JT; Gilje B; Smaaland R; Nordgård O
Clin Breast Cancer; 2010 Oct; 10(5):378-84. PubMed ID: 20920982
[TBL] [Abstract][Full Text] [Related]
8. ESPL1 is a candidate oncogene of luminal B breast cancers.
Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
[TBL] [Abstract][Full Text] [Related]
9. High TIMM17A expression is associated with adverse pathological and clinical outcomes in human breast cancer.
Salhab M; Patani N; Jiang W; Mokbel K
Breast Cancer; 2012 Apr; 19(2):153-60. PubMed ID: 20972741
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer: Role of IGF-1 and IGFBP-3 expression in prognostication.
Raval A; Trivedi S
Indian J Exp Biol; 2016 Oct; 54(10):619-629. PubMed ID: 30084561
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of the insulin-like growth factor-1 ligand and receptor expression in breast cancer tissue.
Chong KY; Subramanian A; Mokbel K; Sharma AK
J Surg Oncol; 2011 Sep; 104(3):228-35. PubMed ID: 21480260
[TBL] [Abstract][Full Text] [Related]
12. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
[TBL] [Abstract][Full Text] [Related]
13. The mRNA expression of inhibitors of DNA binding-1 and -2 is associated with advanced tumour stage and adverse clinical outcome in human breast cancer.
Wazir U; Jiang WG; Sharma AK; Newbold RF; Mokbel K
Anticancer Res; 2013 May; 33(5):2179-83. PubMed ID: 23645773
[TBL] [Abstract][Full Text] [Related]
14. SLC35B2 expression is associated with a poor prognosis of invasive ductal breast carcinoma.
Chim-ong A; Thawornkuno C; Chavalitshewinkoon-Petmitr P; Punyarit P; Petmitr S
Asian Pac J Cancer Prev; 2014; 15(15):6065-70. PubMed ID: 25124574
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma.
Canevari RA; Marchi FA; Domingues MA; de Andrade VP; Caldeira JR; Verjovski-Almeida S; Rogatto SR; Reis EM
Tumour Biol; 2016 Oct; 37(10):13855-13870. PubMed ID: 27485113
[TBL] [Abstract][Full Text] [Related]
16. Detection of circulating cytokeratin-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer.
Tryfonidis K; Kafousi M; Perraki M; Apostolaki S; Agelaki S; Georgoulias V; Stathopoulos E; Mavroudis D
Clin Breast Cancer; 2014 Dec; 14(6):442-50. PubMed ID: 24958324
[TBL] [Abstract][Full Text] [Related]
17. Circulating microRNA-based screening tool for breast cancer.
Frères P; Wenric S; Boukerroucha M; Fasquelle C; Thiry J; Bovy N; Struman I; Geurts P; Collignon J; Schroeder H; Kridelka F; Lifrange E; Jossa V; Bours V; Josse C; Jerusalem G
Oncotarget; 2016 Feb; 7(5):5416-28. PubMed ID: 26734993
[TBL] [Abstract][Full Text] [Related]
18. Negligible nuclear FOXP3 expression in breast cancer epithelial cells compared with FOXP3-positive T cells.
Droeser RA; Obermann EC; Wolf AM; Wallner S; Wolf D; Tzankov A
Clin Breast Cancer; 2013 Aug; 13(4):264-70. PubMed ID: 23829892
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis.
Soufla G; Porichis F; Sourvinos G; Vassilaros S; Spandidos DA
Cancer Lett; 2006 Apr; 235(1):100-13. PubMed ID: 15949894
[TBL] [Abstract][Full Text] [Related]
20. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]